CDT logo

Conduit Pharmaceuticals Inc

CDT

Build a strategy around CDT

Accountable AI Logo

Conduit Pharmaceuticals Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-17

Snapshot

  • Zero revenue TTM with -16.1M FCF burn implies ~3 quarters cash runway at 3.8M current cash position[Free Cash Flow TTM]
  • R&D of 4.4M TTM is just 10% of industry median (45M) - minimal pipeline investment for a pharma company[Research and Development TTM]
  • ROE of -166% and ROIC of -116% TTM reflect pre-revenue biotech destroying capital while seeking clinical validation[Return on Equity]

Watch Triggers

  • Cash and Equivalents: Falls below 2M or rises above 10MBelow 2M = crisis mode; above 10M = successful raise (watch dilution terms)
  • Research and Development TTM: Increases >50% QoQWould signal pipeline acceleration and potential catalyst ahead
  • Total Revenue TTM: Any revenue recognition >0First revenue would transform thesis from speculative to operational

Bull Case

Low debt/equity of 0.44 and minimal long-term debt (8K) means balance sheet is clean for potential acquirer or partnership

Debt to EquityLong Term Debt

Operating expenses of 18.7M TTM are lean vs industry median 101M - efficient burn if pipeline has value

Operating Expense TTM

Bear Case

Cash runway under 3 quarters with zero revenue forces near-term dilution or distressed deal at any price

Cash and EquivalentsFree Cash Flow TTM

R&D spend at 4.4M (10% of peers) suggests limited pipeline advancement capability without major capital raise

Research and Development TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage CDT's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

CDT faces imminent dilution or partnership deal within 12 months to fund operations

3-12mhigh
  • 3.8M cash vs 16M annual burn = <3 quarters runway
  • 6M equity issuance in recent period shows dilution pattern
  • Zero revenue requires external capital for survival
Cash 3.8M, FCF -16.1M TTMIssuance of Capital Stock: 6MTotal Revenue TTM: $0

Valuation Context

Caveats

Public Strategies Rankings

See how Conduit Pharmaceuticals Inc ranks across different investment strategies.

Leverage CDT's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.